Loading stock data…
$59.74-0.17 (-0.29%)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
PTC Therapeutics, Inc. in the Healthcare sector is trading at $60.07 with a market capitalization of $6.1B. Wall Street consensus targets $101.07 (14 analysts), implying a +68.3% move over the next 12 months. The stock is currently near its 52-week low of $59.30, remaining 16.1% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $360.52M↑ | $272.55M↑ | $164.68M↓ | $211.01M↑ | $178.88M |
| Gross Profit | $340.60M↑ | $244.52M↑ | $157.73M↓ | $195.23M↑ | $167.46M |
| Operating Income | $148.98M↑ | $45.89M↑ | -$81.62M↓ | $3.49M↑ | -$34.86M |
| Net Income | $83.50M↑ | -$2.81M↑ | -$134.97M↓ | $15.90M↑ | -$64.85M |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna...